



# An Anti-Inflammatory Biological Candidate

## TECHNOLOGY AVAILABLE FOR TRANSFER

### UNMET NEED & OPPORTUNITY

- Biologics and immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drug classes that will play the main role in the market.<sup>1</sup>
- The demand for anti-inflammatory drugs has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs.
- The rising demand for advanced drugs is likely to create lucrative growth opportunities for the Global Anti-inflammatory Drugs.
- Global Anti-inflammatory therapeutics market projected to US\$ 130.6 Billion by 2026 with CAGR of 8.5% throughout the forecast period from 2018 to 2026.
- Commercially available Biologic Anti-inflammatory drugs are used essentially for Arthritis patients and can be categorized in three such as a. TNF inhibitor, b. B-cell inhibitors, and c. Interleukin-1 blockers.
- The present technology as a product, focuses on a broad-spectrum inflammatory disease and targets inhibition of Mast cells as they are first line of inflammatory response.

### TECHNOLOGY

- The technology is based on the inhibition of mast cells by a protein based drug, which is isolated from *M. tuberculosis*.
- The protein is a member of the PPE family of Mycobacterium tuberculosis characterized by highly conserved Proline-Proline- Glutamate residues, near the start site of their translated proteins.
- Since, mast cells and their inflammatory mediators have an unquestionable role in inflammation caused during tissue therefore, reduction in mast cell population could be an effective approach to treat such problem.

### KEY FEATURES

- It's a broad-spectrum therapy protein drug.
- Non-steroidal anti-inflammatory drug.
- Mast cell inhibitor (disruption of first line inflammatory effect).
- Single dose as injectables (can be developed in other forms such as capsules and ointments).

### STAGE OF DEVELOPMENT

- The technology is at R&D stage with primary proof of concept established at bench scale.




Figure1: The Biological reduces paw edema induced by formalin in mice at early time points

### INTELLECTUAL PROPERTY

- Patent application filed in India in 2018

### LICENSING OPPORTUNITY

BCIL is looking for a suitable industry partner for commercialization of Anti-inflammatory drug.

### REFERENCES

1. <https://www.researchandmarkets.com/reports/4564280/global-anti-inflammatory-therapeutics-market>
2. <https://www.medgadget.com/2019/08/anti-inflammatory-therapeutics-market-perception-to-cross-106-1-bn-by-2020.html>

**CONTACT:**  
**Dr. Yogmaya Verma**  
Deputy Manager

**BIOTECH CONSORTIUM INDIA LIMITED**

V Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110 002

Phone: +91-11-23219064-67, Fax: +91-11-23219063

Email: [yogmaya@biotech.co.in](mailto:yogmaya@biotech.co.in) & [info.bcil@biotech.co.in](mailto:info.bcil@biotech.co.in)

Website: [www.biotech.co.in](http://www.biotech.co.in)